RE: Sir Marc Feldman, Hemo Executive Chairman24 Nov 2020 11:20
JHFH, forgetting all the SP dilution (which we all agree will happen to an extent), all the products as described by Vlad today are pre-clinical validation and/or pre-clinical POC. What's the incentive to buy the share now? What timeframes are these products likely to return any revenue?